AprilBio Co Ltd
KOSDAQ:397030
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
11 070
25 000
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
AprilBio Co Ltd
Cash & Cash Equivalents
AprilBio Co Ltd
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
AprilBio Co Ltd
KOSDAQ:397030
|
Cash & Cash Equivalents
₩6.6B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Cash & Cash Equivalents
₩564.6B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
5%
|
CAGR 10-Years
30%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Cash & Cash Equivalents
₩127B
|
CAGR 3-Years
72%
|
CAGR 5-Years
95%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Cash & Cash Equivalents
₩182.9B
|
CAGR 3-Years
61%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Cash & Cash Equivalents
₩78.4B
|
CAGR 3-Years
51%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Cash & Cash Equivalents
₩27B
|
CAGR 3-Years
15%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
AprilBio Co Ltd
Glance View
AprilBio Co Ltd is a Korea-based company primarily engaged in the biological drug development business. The Company is primarily engaged in the bio-innovative new drug research and development (R&D) business such as antibody therapeutics and long-acting recombinant protein pharmaceuticals.
See Also
What is AprilBio Co Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
6.6B
KRW
Based on the financial report for Dec 31, 2023, AprilBio Co Ltd's Cash & Cash Equivalents amounts to 6.6B KRW.
What is AprilBio Co Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 3Y
-13%
Over the last year, the Cash & Cash Equivalents growth was -10%. The average annual Cash & Cash Equivalents growth rates for AprilBio Co Ltd have been -13% over the past three years .
You don't have any saved screeners yet
